Publication
Maraviroc, as a Switch Option, in HIV-1–infected Individuals With Stable, Well-controlled HIV Replication and R5-tropic Virus on Their First Nucleoside/Nucleotide Reverse Transcriptase Inhibitor Plus Ritonavir-boosted Protease Inhibitor Regimen: Week 4...
Sarah Lilian Pett, Janaki Amin, Andrejz Horban, Jaime Andrade-Villanueva, Marcelo Losso, Norma Porteiro, Juan Sierra Madero, Waldo Belloso, Elise Tu, David Silk, Anthony Kelleher, Richard Harrigan, Andrew Clark, Wataru Sugiura, Marcelo Wolff, John Gill, Jose Gatell, Martin Fisher, Amanda Clarke, Kiat Ruxrungtham, Thierry Prazuck, Rolf Kaiser, Ian Woolley, Juan Alberto Arnaiz, David Cooper, Jürgen K. Rockstroh, Patrick Mallon, Sean Emery
Clinical Infectious Diseases, April 2016, Oxford University Press (OUP)
DOI: 10.1093/cid/ciw207